Clinical trial
A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in Healthy Subjects
NCT05345509 is registered in ClinicalTrials.gov with Inventage Lab., Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in Healthy Subjects
- Lead sponsor
- Inventage Lab., Inc.
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- April 1, 2023
- Completion date
- November 13, 2025
- Enrollment
- 62 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.